Ovarian Cancer Medical Services in China

Ovarian cancer is a malignant neoplasm originating in the ovarian epithelium, stroma, or germ cells, with epithelial ovarian carcinoma accounting for approximately 90% of cases. It is often asymptomatic in early stages, leading to late diagnosis—typically at advanced FIGO stages III or IV—when disease has spread beyond the pelvis. Risk factors include BRCA1/BRCA2 germline mutations, family history, nulliparity, and endometriosis. Standard management involves comprehensive surgical staging or cytoreduction followed by platinum-based chemotherapy (e.g., carboplatin/paclitaxel); PARP inhibitors (olaparib, niraparib) are now integral for maintenance therapy in homologous recombination–deficient tumors. Prognosis remains highly stage-dependent: five-year survival exceeds 90% for localized disease but drops to under 30% in metastatic settings.

China offers compelling advantages for international patients seeking ovarian cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Peking Union Medical College Hospital—boast NCCN-aligned protocols, multidisciplinary tumor boards, and extensive experience in complex cytoreductive surgery and HIPEC. Advanced imaging (3T MRI, PET-CT), robotic-assisted laparoscopy, and next-generation sequencing for molecular profiling are widely available. Clinical outcomes align with global benchmarks: published series report optimal cytoreduction rates >75% in advanced cases and median progression-free survival comparable to Western cohorts. Crucially, treatment costs—including surgery, chemotherapy, and targeted agents—are typically 40–60% lower than in the US or Western Europe, without compromising quality or regulatory oversight (CFDA/NMPA-approved biologics and generics).

As a dedicated medical tourism agency, we facilitate seamless access to these resources: verifying hospital accreditation, coordinating consultations with gynecologic oncologists, securing timely appointments, clarifying all-inclusive pricing upfront, and providing end-to-end support—from visa assistance and translation services to post-treatment follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Ovarian Cancer (Gynecologic Oncology)

Non-Surgical / Medical Therapy

*Indications*: Advanced-stage (III–IV), recurrent disease, neoadjuvant therapy, or medically inoperable patients.

• •First-Line Chemotherapy (Carboplatin + Paclitaxel)

- *Cost per Cycle (3-week regimen)*: - Carboplatin (AUC 5–6): $280–$340 - Paclitaxel (175 mg/m²): $220–$290 - Antiemetics (ondansetron + dexamethasone IV): $45–$65 - Blood count & liver/kidney panel (pre-cycle): $35–$50 - Infusion nursing & monitoring (day-care): $110–$150 - *Total per cycle*: $690–$895 (6 cycles typical)

• •PARP Inhibitors (Maintenance)

- Olaparib (300 mg BID oral): $1,450–$1,720/month - Germline/somatic BRCA testing (NGS panel): $380–$520 - HRD assay (Myriad MyChoice CDx): $620–$790

Surgical / Procedural Options

*Indications*: Stages I–IV; optimal cytoreduction goal ≤1 cm residual disease.

• •Primary Debulking Surgery (PDS)

- *Preoperative Workup*: - Pelvic MRI + contrast: $210–$270 - CA-125 + HE4 + ROMA score: $45–$65 - Cardiopulmonary evaluation (ECG, echo, PFTs if indicated): $180–$240 - *Procedure Cost (open approach, full staging)*: - Total hysterectomy + bilateral salpingo-oophorectomy + omentectomy + pelvic/para-aortic lymphadenectomy + peritoneal biopsies: $4,200–$5,800 - Intraoperative frozen section pathology: $190–$260

• •Interval Debulking Surgery (IDS)

- *Cost range*: $3,900–$5,400 (lower due to reduced complexity vs. PDS)

Special/Complex Scenarios

• •Recurrent Platinum-Resistant Disease:

• •BRCA Wild-Type, HRD-Negative Recurrence:

• •Malignant Bowel Obstruction Palliation:

Quick Selection Guide

• •<60 years, Stage III–IV, good performance status: *PDS + adjuvant chemo + PARPi maintenance* — optimal survival benefit ($12,500–$16,200 total)
• •≥75 years or significant comorbidities (COPD, CHF): *Neoadjuvant chemo → IDS* — lower perioperative risk ($9,800–$13,400)
• •Stage I, low-grade serous or mucinous: *Fertility-sparing surgery (unilateral salpingo-oophorectomy)* — $3,400–$4,600, preserves ovarian function
• •Budget-constrained (<$5,000): *Single-agent carboplatin monotherapy (AUC 5) × 6 cycles* — $4,100–$5,100, modest efficacy but accessible
• •Platinum-resistant recurrence with ascites: *Paracentesis + intraperitoneal cisplatin (off-label)* — $1,200–$1,700/session, palliative symptom control